SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt
This is a single-center, single-arm, phase Ib/II study, aimed at assessing the safety and efficacy of SHR-1501 in combination with SHR-2005 as treatment for patients with high-risk non-muscle invasive bladder cancer (HR NMIBC) which is not completely resectable by transurethral resection of bladder tumor (TURBt).
NMIBC
DRUG: SHR-1501+SHR-2005
Phase I : Incidence of dose limiting toxicities (DLTs), From Day 1 to Day 21|Phase I : RP2D（Recommended Phase 2 dose）, From Day 1 to 90 days after last dose|Phase I : Incidence and severity of adverse events (AEs), From Day 1 to 90 days after last dose|Phase II : CR rate at 3 months, Approximately 2 years
Phase I : CR rate at 3 months, From Day 1 to 90 days after last dose|Phase II : Incidence and severity of adverse events (AEs), Approximately 2 years|Phase Ib/II: PR rate at 3 months, Approximately 2 years|Phase Ib/II: CR rate at 6 months and 12months, Approximately 2 years|Phase Ib/II: Duration of CR (DoR), Approximately 2 years|Phase Ib/II: Cystectomy-Free Survival (CFS), Approximately 2 years
This is a single-center, single-arm, phase Ib/II study, aimed at assessing the safety and efficacy of SHR-1501 in combination with SHR-2005 as treatment for patients with high-risk non-muscle invasive bladder cancer (HR NMIBC) which is not completely resectable by transurethral resection of bladder tumor (TURBt).